A better buy-in window may exist right now for Heron Therapeutics Inc (HRTX)

With 1.26 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.06 million shares. The 52-week range on HRTX shows that it touched its highest point at $3.22 and its lowest point at $0.50 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.69.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRTX was down-trending over the past week, with a drop of -8.75%, but this was up by 1.88% over a month. Three-month performance surged to 55.75% while six-month performance rose 179.38%. The stock gained 60.36% in the past year, while it has gained 59.41% so far this year. A look at the trailing 12-month EPS for HRTX yields -0.87 with Next year EPS estimates of -0.06. For the next quarter, that number is -0.07. This implies an EPS growth rate of 73.33% for this year and 70.31% for next year. EPS is expected to grow by 47.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 20.01%.

Float and Shares Shorts:

At present, 150.29 million HRTX shares are outstanding with a float of 142.74 million shares on hand for trading. On Mar 15, 2024, short shares totaled 25.43 million, which was 16.91% higher than short shares on Feb 15, 2024. In addition to Mr. Craig Alexander Collard as the firm’s CEO & Director, Ms. Ira Duarte serves as its Executive VP & CFO.

Institutional Ownership:

Through their ownership of 76.09% of HRTX’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRTX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, HRTX has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and HRTX currently yields $0.00. In the past year, HRTX’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, HRTX has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.